Introduction {#Sec1}
============

RA is a common, complex autoimmune disorder characterized by a chronic and destructive inflammation localized in the synovial lining of diarthrodial joints \[[@CR1]\]. Accumulated evidence suggests that the inflammatory response in the rheumatoid joints is driven by antigen-specific T cells and B cells. The disease-causing antigens are not known, but it appears that disease-specific B cells produce antibodies specific to citrullinated proteins \[[@CR1], [@CR2]\]. These anti-citrullinated protein antibodies (ACPA) represent disease-specific markers used for the diagnosis of RA, which can appear several years before the onset of the disease and whose presence is associated with a more severe disease course \[[@CR3], [@CR4]\]. Protein-bound arginine residues are deiminated to citrulline by the Ca^2+^-dependent peptidylarginine deiminase family, of which the human isoform 4 (hPAD4) is a target of autoantibodies in RA patients \[[@CR5]--[@CR9]\]. We have recently shown in a large RA cohort that the presence of anti-hPAD4 autoantibodies at baseline is associated with radiographic damage after 10 years \[[@CR6]\]. It is not known why serum anti-hPAD4 antibodies are associated with a more aggressive disease course.

In the present work, we have addressed two key issues related to the anti-hPAD4 immune response in RA. We have investigated whether the level of serum anti-hPAD4 IgG is stable over a period of 10 years and tested the possibility that the antibodies could contribute to the formation of citrullinated epitopes by affecting the activity of the enzyme.

Materials and methods {#Sec2}
=====================

Chemicals {#Sec3}
---------

*N*-α-Benzoyl-[l]{.smallcaps}-arginine ethyl ester (BAEE), β-NADH, glutathione, α-ketoglutaric acid, isopropyl β-D-thiogalactopyranoside (IPTG), bovine liver glutamate dehydrogenase (GDH), and 3-\[*N*-morpholino\] propane sulfonic acid (MOPS) were from Sigma--Aldrich (St-Louis, USA). Glutathione-Sepharose 4B, Pre-scission protease, and Protein G Sepharose^TM^ 4 Fast Flow were from GE Healthcare Bio- Sciences AB (Uppsala, Sweden). BCA reagents were from Pierce (Rockford, USA).

Patients and sera {#Sec4}
-----------------

Serum samples from baseline and after 10 years were available from 128 patients in the previously described Norwegian EURIDISS cohort \[[@CR6]\]. At baseline, these patients had a disease duration of 2.5 (±1.2) years. The control group (*n* = 120) consisted of healthy individuals selected from the population register after matching for age, sex, and residential area with patients in the Oslo RA register.

hPAD4 and the anti-hPAD4 antibody assay {#Sec5}
---------------------------------------

The full-length hPAD4 cDNA was provided by Dr. Akihito (Tokyo Metropolitan Institute of Gerontology, Japan), expressed as a fusion protein with glutathione S-transferase (GST) and purified as previously described \[[@CR6], [@CR10]\]. For an aliquot of hPAD4, GST was cleaved off by Pre-scission protease. Enzymatic activities were tested with BAEE and proteins (fibrinogen, ovalbumin, catalase) as substrates, using a colorimetric assay \[[@CR11]\] and the Anti-Citrulline (modified) Detection Kit (Millipore/Temecula, CA/USA), respectively. Serum anti-hPAD4 IgG antibodies were detected by our previously described hPAD4-specific immunoassay \[[@CR6]\].

IgG purification {#Sec6}
----------------

Five serum samples exhibiting high levels of anti-hPAD4 IgG and two sera negative for anti-hPAD4 IgG were selected from the Oslo RA registry cohort \[[@CR6]\]. Three controls were selected from the healthy control group. Total IgG was purified using Sepharose beads conjugated with protein G according to the manufacturer's instructions. IgG was eluted with 5 × 100 μl 0.1 M glycine/HCl pH 2.5 and collected in the tubes containing 8 μl 1 M Tris/HCl pH9.0 to neutralize the pH. Purified IgG was dialyzed against 100 mM MOPS pH 7.4, and protein concentration was determined by the method of Bradford using a BCA kit and human immunoglobulins as a standard (Octapharma A.S., Norway). Purity was confirmed by SDS--PAGE.

Depletion of anti-hPAD4 antibodies from total IgG {#Sec7}
-------------------------------------------------

Purified total IgG was dialyzed against 100 mM MOPS pH 7.4/1.5 mM Ca^2+^. In order to deplete anti-hPAD4 IgG, the dialyzed samples were passed through an affinity column consisting of purified GST-hPAD4 bound to glutathione-Sepharose 4B. Two mock depletion controls were included: a fraction of the total IgG was passed through a glutathione-Sepharose 4B column and the MOPS/Ca^2+^ buffer was passed through a GST-hPAD4-glutathione-Sepharose 4B column. Depletion efficiency was verified by the hPAD4-specific immunoassay.

Kinetic assay {#Sec8}
-------------

The ammonium-release assay has been described previously \[[@CR10]\]. Briefly, the reaction mixtures (final volume of 60 μl) contained 100 mM MOPS pH 7.4, 1 mM β-NADH, 10 mM α-ketoglutaric acid, 3.95 U GDH, 1.5 mM Ca^2+^, 1 μg purified hPAD4 (0.18 U), and different amounts of the substrate BAEE (0--10 mM). GDH, β-NADH, and α-ketoglutarate solutions were freshly prepared, and reactions were carried out in Maxisorp 96-well plates (Nunc, Rochester, USA). Mixtures were pre-incubated for 10 min at 37°C in the presence of 110 μg/ml purified IgG, and reactions were started by the addition of BAEE. Decrease in absorbance at 340 nm was measured in a 1420 VICTOR^3TM^ multilabel counter (Perkin-Elmer, Wallac, Finland). β-NADH concentration was determined based on a β-NADH standard curve (0--1 mM). Initial velocities obtained from these experiments were plotted over the substrate concentration (Michaelis--Menten plot). Experiments without BAEE were carried out to control for citrullination of proteins present in the assay (IgG, GDH, hPAD4), which would alter the kinetics (data not shown).

Statistical analyses {#Sec9}
--------------------

Analyses were performed using GraphPad InStat version 3.06 for Windows, GraphPad Software (San Diego, USA).

Results {#Sec10}
=======

Anti-hPAD4 IgG in RA sera at baseline and after 10 years {#Sec11}
--------------------------------------------------------

To ensure a low inter-assay variability of our assay, the 128 baseline RA sera were retested and the measured levels of anti-hPAD4 IgG antibodies were compared with our previously published data \[[@CR6]\]. Reproducibility of data was confirmed by a linear correlation test (*r* = 0.96) (Fig. [1](#Fig1){ref-type="fig"}). In the majority of the 128 RA patients, we observed that the baseline levels of anti-hPAD4 IgG antibodies remained stable over 10 years (Fig. [2](#Fig2){ref-type="fig"}a). Three sera that had low levels of anti-hPAD4 IgG at baseline had become negative at 10 years. Interestingly, seven sera, which were anti-hPAD4 negative at baseline, had become positive after 10 years (Fig. [2](#Fig2){ref-type="fig"}b). Among these, four sera were anti-CCP2 positive at baseline and after 10 years. Radiographic joint damage data after 10 years were available for six of these seven patients and showed that five out of these six had severe erosive disease with a total van der Heidje modified Sharp score above 30 (data not shown). As shown in our previous study, anti-hPAD4 IgG levels correlate with the levels of anti-CCP antibodies and a higher longitudinal radiographic damage score \[[@CR6]\].Fig. 1Inter-assay variability of the anti-hPAD4 immunoassay. The level of anti-hPAD4 IgG (expressed as emission signals) was assessed at *baseline* in sera from 128 patients in the EURIDISS RA cohort, and the results were compared with our previously published data on the same sera. The correlation analysis (*r* = 0.96) confirmed that the results were reproducibleFig. 2**a** Assessment of serum anti-hPAD4 IgG levels in RA sera at *baseline* and after 10 years. The sera were diluted 1:2,000 before incubation, measurements were taken in duplicates, and the anti-hPAD4 IgG levels are expressed as the mean emission signal after subtraction of the background signal. **b** Assessment of serum anti-hPAD4 IgG levels in RA sera at *baseline* and after 10 years. Depicted are the three patients who were anti-hPAD4 positive at baseline and negative after 10 years, and the seven patients who were anti-hPAD4 negative at *baseline* and positive after 10 years. The sera were diluted 1:2,000 before incubation, measurements were taken in duplicates, and the anti-hPAD4 IgG activity levels are expressed as the mean emission signal after subtraction of the background signal

Influence of anti-hPAD4 antibodies on hPAD4 catalytic activity {#Sec12}
--------------------------------------------------------------

The range of anti-hPAD4 IgG concentrations used in the kinetic assay was chosen according to the method employed by Kiraly et al. \[[@CR12]\]. First, purified IgG was titrated in the hPAD4-specific immunoassay in order to determine the IgG concentration that gave maximal absorbance. To ensure sufficient concentrations of anti-hPAD4-specific antibodies in the hPAD4 kinetic assay, we applied a concentration of purified IgG that was 30-fold higher than the value determined by these titration experiments (i.e., 110 μg/ml). In additional control experiments, concentrations as high as 400 μg/ml of purified IgG were tested.

The purified serum IgG fractions were then subjected to depletion of anti-hPAD4 antibodies. As evaluated by the hPAD4-specific immunoassay, this procedure resulted in quantitative removal of anti-hPAD4 IgG (Fig. [3](#Fig3){ref-type="fig"}a). The effects of the purified serum IgG fractions and of the anti-hPAD4-depleted IgG fractions on hPAD4 activity were assessed by the ammonium-release assay. The *k*~*cat*~ and *K*~*m*~ values for hPAD4-catalyzed deimination of BAEE were determined in the presence of total IgG fractions or IgG fractions depleted from anti-hPAD4. To ensure that the depletion procedure itself did not affect the measured kinetic parameters, we also performed the assay in the presence of mock-depleted IgG. Interestingly, similar *k*~*cat*~*/K*~*m*~ values were found under all these conditions (Fig. [3](#Fig3){ref-type="fig"}b and Table [1](#Tab1){ref-type="table"}), suggesting that anti-hPAD4 antibodies do not interfere with enzymatic activity.Fig. 3**a** Detection of anti-hPAD4 antibodies in serum, in total IgG purified from the same serum, in serum depleted from anti-hPAD4 antibodies, and in mock depletion controls. The hPAD4-specific fluorometric immunoassay was used, and results from three individual sera are shown; patients *RA64* (anti-hPAD4 positive) and *RA39* (anti-hPAD4 negative) and the healthy control *HC80*. The sera and the IgG fractions were diluted 1:2,000 before incubation. **b** Influence of anti-hPAD4 antibodies on hPAD4-mediated deimination of BAEE. Shown are the relative *k*~*cat*~/*K*~*m*~ values for the total IgG fraction, IgG depleted from anti-hPAD4 antibodies, and the mock-depleted total IgG. Data are shown for five anti-hPAD4-positive and two anti-hPAD4-negative RA patients and for three healthy controls. The *k*~*cat*~/*K*~*m*~ value for each total IgG fraction was normalized to one. All the experimental *k*~*cat*~/*K*~*m*~ values are provided in Table [1](#Tab1){ref-type="table"}. (\*) *k*~*cat*~/*K*~*m*~ value was not determinedTable 1Parameters *k*~*cat*~ and *K*~*m*~ as measured in the kinetic assayRA sera (anti-hPAD4 emission signals \[x10^6^\])Purified total IgGPurified total IgG depleted from anti-hPAD4 antibodiesControl depletion*K*~*m*~ \[mM\]*k*~*cat*~ \[s^−1^\]*k*~*cat*~*/K*~*m*~ \[s^−1^ M^−1^\]*K*~*m*~ \[mM\]*k*~*cat*~ \[s^−1^\]*k*~*cat*~*/K*~*m*~ \[s^−1^ M^−1^\]*K*~*m*~ \[mM\]*k*~*cat*~ \[s^−1^\]*k*~*cat*~*/K*~*m*~ \[s^−1^ M^−1^\]Anti-PAD4-positive sera RA26 (1.59)1.355.263,8900.853.383,9700.83.384,225 RA35 (1.43)1.603.752,3401.603.752,3401.603.752,340 RA64 (1.59)1.405.203,7101.505.603,7301.505.203460 RA78 (1.02)1.405.263,7501.305.264,0401.255.264,200 RA99 (1.14)1.003.383,3801.253.002,4001.303.002,300Anti-PAD4-negative sera RA39 (0.023)1.205.514,5911.496.194,1541.254.873,896 RA55 (0.021)1.504.503,0001.753.602,0501.453.382,330Healthy control sera HC74 (0.032)1.502.251,5001.202.632,192ndndnd HC80 (0.016)0.752.403,2000.752.633,5060.752.253,000 HC89 (0.046)1.203.382,8101.203.002,5001.203.002,500 Buffer control (0.005)0.902.632,900Recombinant hPAD4 was incubated with purified IgG or with MOPS buffer. The values shown are from one representative experiment. Anti-hPAD4 emission signals were obtained in the hPAD4-specific fluorometric immunoassay

Discussion {#Sec13}
==========

The role of hPAD4 in RA has been extensively studied during the last years. Several studies found an association between polymorphisms in the hPAD4 gene and disease risk \[[@CR8], [@CR13]--[@CR15]\]. Furthermore, antibodies directed against hPAD4 have been identified and shown to be associated with anti-CCP positivity, progressive disease, and also persistent radiographic damage in RA patients receiving anti-TNF-α therapy \[[@CR6], [@CR8]\].

We have previously shown anti-hPAD4 data at baseline from 237 patients in the EURIDISS RA cohort \[[@CR6]\]. Now, we present the 10-year follow-up data on 128 patients from this EURIDISS cohort which show that individual RA patients have remarkably stable titers of anti-PAD4 antibodies. Only seven RA patients who were initially anti-hPAD4 negative had become positive at follow-up. It is interesting, however, to note that disease progressed in five of six of these patients from whom we had radiographic joint damage data.

Serum anti-hPAD4 IgG, similarly to the anti-CCP antibodies \[[@CR16]\], appears early in the disease course and remains present in the serum over time. Whether they contribute to the chronicity of the disease is unclear. We hypothesized that the antibodies could influence the activity of the enzyme in vivo and thereby modulate the protein citrullination process. For other human diseases, such as Wegener's granulomatosis and autoimmune thyroiditis, it has been suggested that the binding of specific antibodies to enzymes affects the activity of the enzyme \[[@CR17], [@CR18]\]. However, under our experimental conditions, we did not find that the anti-hPAD4 IgG antibodies had an effect on hPAD4-mediated deimination of a model substrate. This result does not exclude that anti-hPAD4 antibodies may have effects on the enzyme in vivo. It is, for instance, possible that the binding of the anti-hPAD4 antibodies may stabilize the enzyme and protect it from degradation. An alternative explanation might be that PAD4-containing immune complexes have pro-inflammatory properties that contribute to the more pronounced joint erosion observed in the anti-hPAD4-positive patients.

In contrast to our results, Auger et al. \[[@CR19]\] recently published that anti-hPAD4 antibodies inhibit hPAD4-mediated citrullination of fibrinogen. It should be noted that they used an approach different from ours to address the effect of those antibodies on hPAD4 activity. Whereas Auger et al. used a protein substrate of hPAD4, our experiments were carried out with the small arginine-derivative BAEE. As anti-PAD4 autoantibodies may not only directly influence the enzymatic activity but could also interfere with substrate binding, the small BAEE molecule may still be able to enter the active site whereas binding of the large substrate fibrinogen may be sterically blocked. Notably, antibody binding to the C-terminal part of PAD4, which contains the active site \[[@CR20]\], has been demonstrated \[[@CR8], [@CR19]\]. Secondly, Auger et al. purified hPAD4-specific antibodies using hPAD4 adsorbed to the surface of ELISA plates, whereas we used sera depleted from hPAD4 antibodies by capturing them on a GST--PAD4 affinity matrix. It might therefore be that the antibodies explored in both studies fall into two populations that are not exactly identical. For example, absorption of PAD4 to the plate may induce changes in the enzyme's tertiary structure \[[@CR21]\] that is likely to affect the binding of antibodies directed against conformational epitopes. Although a direct comparison of the results obtained from both studies appears difficult, they can be considered as supplementary data describing the influence of anti-PAD4 autoantibodies on the enzymatic activity.

In conclusion, we confirm that anti-hPAD4 antibodies, which are a useful marker of disease severity in RA at baseline, do not disappear over time. However, our study does not show an effect of anti-hPAD4 IgG on the activity of the hPAD4 enzyme when a small substrate is used. Further investigations into the mechanisms that link anti-hPAD4 antibodies to erosive disease and resistance to anti-TNFα treatment are therefore required in the future.
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